GlassScriptPhysician profile
James M King
NPI 1285456293
$1,737.87
in general payments reported to CMS, 2019-2025
24 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $260.50 | 2025 | Wegovy |
| Abbvie INC. | $237.38 | 2025 | |
| Pfizer INC. | $145.16 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $137.52 | 2025 | Airsupra |
| Lilly USA, LLC | $130.33 | 2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $89.77 | 2025 | |
| Madrigal Pharmaceuticals | $83.06 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $75.02 | 2025 | Voquezna |
| Lundbeck LLC | $59.87 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $56.76 | 2025 | Rexulti |
| Insulet Corporation | $56.52 | 2025 | Omnipod |
| Mannkind Corporation | $55.25 | 2025 | |
| Exact Sciences Corporation | $43.50 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $43.15 | 2025 | Trelegy Ellipta, Shingrix |
| Optinose US, INC. | $42.56 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $41.98 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.20 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $23.60 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.41 | 2025 | Jardiance |
| Phadia US INC. | $21.18 | 2025 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $21.10 | 2025 | |
| Beta Bionics, INC. | $18.22 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Inspire Medical Systems, INC. | $17.45 | 2025 | Inspire |
| Verrica Pharmaceuticals INC. | $15.38 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.